Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mohammad Qasaymeh

Neurology with Special Qualifications in Child Neurology Amherst, NY Medical Doctor

NPI 1528074341 CMS profile 114077

3980 Sheridan Dr, Amherst, NY 14226

Open in the dashboard

General payments

$42,412

780 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$1,020,031

7 holdings reported · through program year 2025

Through program year 2025, Mohammad Qasaymeh of Amherst, NY is reported in the CMS Open Payments database as having received $42,412 across 780 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $1,020,031 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,146 89
2024 General $2,386 105
2023 General $2,702 134
2022 General $5,048 140
2021 General $25,172 144
2020 General $1,894 56
2019 General $3,064 112
2025 Ownership $420,282 1
2024 Ownership $250,919 1
2023 Ownership $152,600 1
2022 Ownership $104,985 1
2021 Ownership $52,874 1
2020 Ownership $29,736 1
2019 Ownership $8,635 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mohammad Qasaymeh
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Mohammad Qasaymeh were reported at $2,146. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Mohammad Qasaymeh Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $3,064 $262 $68–$1,313 $163
2020 $1,894 $188 $46–$1,222 $114
2021 $25,172 $183 $45–$1,356 $132
2022 $5,048 $229 $72–$1,177 $149
2023 $2,702 $269 $93–$1,195 $160
2024 $2,386 $300 $98–$1,428 $164
2025 $2,146 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biohaven Pharmaceuticals, Inc. $21,282 57 payments
  2. AbbVie, Inc. $5,482 101 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $2,810 22 payments
  4. LivaNova USA, Inc. $2,534 65 payments
  5. UCB, Inc. $1,896 88 payments
  6. SK Life Science, Inc. $793 24 payments
  7. Teva Pharmaceuticals USA, Inc. $761 39 payments
  8. Pfizer Inc. $734 42 payments
  9. Jazz Pharmaceuticals Inc. $576 21 payments
  10. Allergan Inc. $509 15 payments
  11. Other $5,033 306 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,000 12 payments
  2. Food and Beverage $15,124 749 payments
  3. Travel and Lodging $2,950 14 payments
  4. Consulting Fee $1,185 1 payment
  5. Education $154 4 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT Primary Care $24,092 79 payments
  2. UBRELVY $4,386 46 payments
  3. VNS Therapy $1,711 24 payments
  4. QULIPTA $1,305 53 payments
  5. Briviact $855 40 payments
  6. Epidiolex $787 39 payments
  7. BOTOX $652 29 payments
  8. AJOVY $582 29 payments
  9. NURTEC ODT Pain $575 40 payments
  10. Nayzilam $475 19 payments
  11. Other $7,484 417 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$4,412

Medicare's payments for the services billed

Medicare patients

18

Average age 43

Services billed

118

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Nayzilam
  • UCB, Inc. $274
$274 — —
UBRELVY
  • AbbVie, Inc. $255
$255 — —
QULIPTA
  • AbbVie, Inc. $229
$229 — —
BOTOX
  • AbbVie, Inc. $192
$192 — —
KOSELUGO
  • Alexion Pharmaceuticals, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

780 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record